Get the Stockscreener App
7.415
21.12%
-1.985
After Hours:
7.54
0.125
+1.69%
Immunitybio Inc stock is traded at $7.415, with a volume of 86.62M.
It is down -21.12% in the last 24 hours and down -35.80% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$9.40
Open:
$9.075
24h Volume:
86.62M
Relative Volume:
2.40
Market Cap:
$7.62B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-19.02
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-9.68%
1M Performance:
-35.80%
6M Performance:
+196.60%
1Y Performance:
+160.18%
1-Day Range:
$6.54
$9.1499
1-Week Range:
$6.54
$9.54
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.415 | 9.66B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.50B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX - Business Wire
Biopharma bites: ImmunityBio's 'misleading' ad, UCB's manufacturing hub, plus Aardvark's obesity pause - FirstWord Pharma
ImmunityBio (NASDAQ:IBRX) Trading Down 21.1%Time to Sell? - MarketBeat
Is ImmunityBio (IBRX) Still Attractive After A 365% Year To Date Surge - simplywall.st
ImmunityBio Gains on Anktiva Approval in Macau, First in Asia | 2026News and Statistics - IndexBox
ImmunityBio Stock Falls on FDA Warning. No, Its Drug Can’t ‘Treat All Cancers.’ - Barron's
FDA Flags Misleading Claims on Cancer Drug Made by Billionaire Owner of ImmunityBio - MedPage Today
ImmunityBio stock price crash: buy the dip or sell the rip? - Invezz
Biotech Billionaire Gets FDA Warning Over Cancer Drug Claims - Fine Day 102.3
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - Yahoo Lifestyle Canada
BTIG reiterates Immunitybio stock Buy rating after FDA warning - Investing.com
“FDA Warning” on Cancer Drug Sends ImmunityBio Stock (IBRX) Tumbling over 26% - TipRanks
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Why ImmunityBio Stock Is Down More Than 20% Today - The Motley Fool
ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode - Fierce Pharma
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy - Yahoo Finance
Promising Biotech Stocks Worth WatchingMarch 24th - MarketBeat
US FDA sends warning letter to ImmunityBio for "false or misleading" TV ad and podcast on Anktiva - marketscreener.com
FDA slams Soon-Shiong and ImmunityBio for making 'false and misleading' claims about a drug - statnews.com
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad - TradingView
ImmunityBio initiates review after receiving FDA letter on Anktiva promotional materials - marketscreener.com
ImmunityBio Plunges After Getting FDA Warning on Cancer Drug Anktiva - Bloomberg.com
ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials - TradingView
FDA warns ImmunityBio over misleading podcast with Patrick Soon-Shiong - Endpoints News
Why ImmunityBio’s cancer drug claims alarmed the FDA - Rolling Out
ImmunityBio Faces Market Impact After Large Share Sale - StocksToTrade
ImmunityBio (IBRX) Shares Plunge 21% Following FDA Warning Letter on Misleading Cancer Drug Marketing - Blockonomi
ImmunityBio shares plunge after FDA warning over misleading ads - Investing.com
ImmunityBio (IBRX) Stock Drops 21% After FDA Says Its Cancer Drug Ads Broke the Law - CoinCentral
ImmunityBio stock falls after FDA warning (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Plunges After Getting FDA Warning on Cancer Drug - Bloomberg.com
A Look At ImmunityBio (IBRX) Valuation After ANKTIVA’s Macau Approval And NCCN Guideline Expansion - Yahoo Finance
ImmunityBio (IBRX) Soars 11% as Asian Expansion Looms - Insider Monkey
IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits
10 Stocks to Watch Today: QXO, ImmunityBio, PayPay, and More - Insider Monkey
ImmunityBio (NASDAQ:IBRX) Shares Up 11%Here's What Happened - MarketBeat
Why ImmunityBio Stock Is Up More Than 11% Today - AOL.com
Why ImmunityBio Stock Is Up More Than 11% Today - The Motley Fool
ImmunityBio’s Asia Expansion: Macau Greenlights Anktiva for Bladder Cancer - StocksToTrade
ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for Papillary-Only NMIBC - Insider Monkey
ImmunityBio Receives Critical Approvals, Sees Significant Stock Gains - timothysykes.com
ImmunityBio's (IBRX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
NCCN Adds ImmunityBio’s Anktiva to Bladder Cancer Guidelines - Oncodaily
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX? - Yahoo Finance
ImmunityBio Inc stock surges on promising Phase 3 cancer vaccine data amid biotech rally - AD HOC NEWS
ImmunityBio (IBRX) climbs 7.3% as firm nears development of 'world bank of NK cells' - MSN
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway - Yahoo Finance
Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era” - Insider Monkey
Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.80%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):